Primary lung cancer: Biodistribution and dosimetry of two In-111-labeled monoclonal antibodies

P. H. Brown, G. T. Krishnamurthy, F. E. Turner, R. K. Denney, S. A. Gilbert, M. E. Slauson

Research output: Contribution to journalArticlepeer-review

1 Scopus citations


This study was undertaken to measure the biokinetics and organ dosimetry of indium-111-labeled monoclonal antibodies (MoAbs) with a whole-body gamma camera imaging technique. Twenty patients with primary lung cancer were studied with two different MoAb agents (anti-carcinoembryonic antigen ZCE025 and antiadenocarcinoma LA20207). Imaging was performed at 1, 24, 72, and 144 hours after injection. Scintigraphic wholebody retention was verified by means of comparison with the results from in vitro counting of excreta. Organ retention was verified in an abdominal phantom. The MoAb cleared slowly from the heart and lungs, the brain and spleen showed no clearance, and the liver showed increased activity over the 6-day period. Dosimetry for ZCE025 showed a dose to the liver of 1.3 rad/mCi (0.36 mGy/MBq); heart, 1.5 rad/mCi (0.40 mGy/MBq); spleen, 1.1 rad/mCi (0.29 mGy/MBq); total body, 0.49 rad/mCi (0.13 mGy/MBq); and testes, 0.39 rad/mCi (0.11 mGy/MBq). The dosimetry for LA20207 was similar.

Original languageEnglish (US)
Pages (from-to)701-705
Number of pages5
Issue number3
StatePublished - Jan 1 1989


  • Lung neoplasms, radionuclide studies
  • Monoclonal antibodies
  • Radionuclide imaging, computer assisted
  • Radionuclide imaging, dosimetry
  • Radionuclide imaging, radiation dose

ASJC Scopus subject areas

  • Radiology Nuclear Medicine and imaging


Dive into the research topics of 'Primary lung cancer: Biodistribution and dosimetry of two In-111-labeled monoclonal antibodies'. Together they form a unique fingerprint.

Cite this